Camila Simões

Assistant Professor

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

Pathology, College of Medicine

7 h-index 48 pubs 135 cited

Research Areas

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Camila Simões investigates the potential of oncolytic viruses and immune checkpoint inhibitors for treating liver cancers, particularly hepatocellular carcinoma. Her recent work explores repurposing existing vaccines, such as the trivalent MMR vaccine, as cost-effective cancer immunotherapies. Simões also studies dietary interventions, like methionine restriction, to enhance responses to immune checkpoint inhibitors in colorectal cancer models. She has published on the characterization of Morreton virus (MORV) as a novel oncolytic virotherapy platform for liver cancers and the enhancement of neoadjuvant virotherapy for pancreatic cancer by targeting the tumor stroma. Her research network includes collaborators from the University of Arkansas for Medical Sciences, such as Steven R. Post, Martin J. Cannon, Alexei G. Basnakian, and Mulu Z. Tesfay, with whom she has co-authored multiple publications. Simões's scholarship metrics include an h-index of 7, 50 total publications, and 131 total citations.

Metrics

h-index: 7
Publications: 48
Citations: 135

Selected Publications

Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)

DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

1 citation DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025)

DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

4 citations DOI OpenAlex
S3275 A Case of “Black Esophagus” Following Esophageal Candidiasis (2024)

DOI OpenAlex
S5193 More Than Just a Variceal Bleed: Multiple Portal Hypertensive Gastric Polyps in a Case of Advanced Cirrhosis (2024)

DOI OpenAlex
Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease (2024)

4 citations DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

4 citations DOI OpenAlex
Abstract 588: Preclinical evaluation of novel chimeric vesiculovirus mediated expression of proteolytic enzymes targeting two major stromal components of pancreatic ductal adenocarcinoma (2024)

DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

DOI OpenAlex
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model (2023)

25 citations DOI OpenAlex
S3266 A Comparison of Two Cases of Acute Graft versus Host Disease Following Liver Transplant (2022)

1 citation DOI OpenAlex
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)

6 citations DOI OpenAlex
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers (2022)

13 citations DOI OpenAlex